IBCG Risk Stratification Model for Intermediate-Risk NMIBC

Authored by Ashish Kamat, published on 2026-04-10 20:56:45.0

Intermediate-Risk Non–Muscle-Invasive Bladder Cancer (IR NMIBC) Risk Stratification Model by the International Bladder Cancer Group (IBCG).

IR NMIBC includes low-grade tumors only — all high-grade tumors require high-risk pathways
Assess five clinical risk factors (tap or click for details)

Tumor multifocality Tumor size ≥3 cm Early recurrence <1 yr Frequent recurrences >1/yr, Prior intravesical therapy failure
- Score (0–5)
  
  Add one for each risk factor: Tumor multifocality Tumor size ≥3 cm Early recurrence <1 yr Frequent recurrences >1/yr Prior intravesical therapy failure
  - Lower risk (0 risk factors)
    - De-intensify (Consider active surveillance)
  - Intermediate risk (1–2 risk factors)
    - Standard therapy (Risk-adapted intravesical treatment)
  - Higher risk (≥3 risk factors)
    - Intensify (Adjuvant therapy escalation)

tos privacy Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance